{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:31:34Z","timestamp":1791297094446,"version":"4.1.0"},"reference-count":14,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2009,8,7]],"date-time":"2009-08-07T00:00:00Z","timestamp":1249603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:sec><jats:label\/><jats:p> <jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003Conflicting studies have raised uncertainty over the vascular effects of the long\u2010acting anticholinergic, tiotropium bromide.<\/jats:p><jats:p> <jats:bold>WHAT THIS STUDY ADDS<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003Our results show no increased risk of stroke with tiotropium bromide, or with inhaled anticholinergics in general.<\/jats:p><\/jats:sec><jats:sec><jats:title>AIMS<\/jats:title><jats:p>A recent communication from the United States Food and Drug Administration highlighted a possible increased risk of stroke associated with use of the relatively new inhaled anticholinergic drug, tiotropium bromide. Using the United Kingdom General Practice Research Database, we set out to assess the risk of stroke in individuals exposed to inhaled tiotropium bromide and two other inhaled treatments for airways disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>We used the self\u2010controlled case\u2010series that reduces confounding and minimizes the potential for biases in the quantification of risk estimates.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Of 1043 people with a diagnosis of incident stroke who had had at least one prescription for tiotropium bromide, 980 satisfied inclusion criteria. The age\u2010adjusted incidence rate ratio for all\u2010cause stoke in individuals exposed to tiotropium bromide (<jats:italic>n<\/jats:italic>= 980), ipratropium bromide (<jats:italic>n<\/jats:italic>= 4181) and fluticasone propionate\/salmeterol xinafoate (<jats:italic>n<\/jats:italic>= 1000) was 1.1 [95% confidence interval (CI) 0.9, 1.3], 0.8 (95% CI 0.7, 0.9) and 1.0 (95% CI 0.9, 1.2), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>We found no evidence of an increased risk of all\u2010cause stroke for individuals exposed to commonly prescribed inhaled treatments for chronic obstructive pulmonary disease.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2009.03517.x","type":"journal-article","created":{"date-parts":[[2009,8,7]],"date-time":"2009-08-07T12:04:46Z","timestamp":1249646686000},"page":"731-736","source":"Crossref","is-referenced-by-count":9,"title":["Inhaled tiotropium bromide and risk of stroke"],"prefix":"10.1111","volume":"68","author":[{"given":"Anthony","family":"Grosso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aroon D.","family":"Hingorani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"MacAllister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hubbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam","family":"Smeeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,11,6]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60694-7"},{"key":"e_1_2_7_3_2","unstructured":"US Food and Drug Administration.Early communication about an ongoing safety review of tiotropium (marketed as Spiriva HandiHaler). Available athttp:\/\/www.fda.gov\/cder\/drug\/early_comm\/tiotropium.htm(last accessed 20 July 2008)."},{"key":"e_1_2_7_4_2","unstructured":"Spiriva HandiHaler (tiotropium bromide) Summary of Product Characteristics.Boehringer Ingelheim. Available athttp:\/\/emc.medicines.org.uk\/emc\/industry\/default.asp?page=displaydoc.asp&documentid=10039(last accessed 20 August 2008)."},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805800"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.00537.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a1069"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03273.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a1227"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2005.041798"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S1516"},{"key":"e_1_2_7_12_2","unstructured":"General practice research database. Available athttp:\/\/www.gprd.com\/home\/(last accessed 25 March 2008)."},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.2307\/2533328"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00023907"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000134294.54422.2e"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2009.03517.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2009.03517.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T02:39:41Z","timestamp":1697423981000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2009.03517.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1111\/j.1365-2125.2009.03517.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03517.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}